Related Experiment Video
Updated: May 11, 2026
07:41
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
MED1101: a new dialdehydic compound regulating P2×7 receptor cell surface expression in U937 cells
Stefania Muzzachi1, Antonella Blasi, Elena Ciani
1Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, 70126, Italy.
Biology of the Cell
|May 31, 2013
Summary
MED1101 acts as a P2×7 receptor antagonist by causing receptor internalization and inhibiting monocyte migration. This suggests MED1101 has therapeutic potential for inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- P2×7 receptor (P2×7R) is activated by extracellular ATP during inflammation and is expressed in immune cells.
- P2×7R antagonists are being investigated as therapeutics for inflammatory diseases.
- MED1101 is a novel dialdehydic compound tested for P2×7R antagonist activity.
Purpose of the Study:
- To investigate the P2×7 receptor antagonist effect of MED1101.
- To evaluate MED1101's impact on U937 monocyte cells.
Main Methods:
- U937 monocyte cells were used to assess P2×7R expression and response to LPS.
- MED1101's effect on P2×7R internalization and monocyte migration was measured.
- Intracellular signaling pathways (Ca2+ influx, MAPK phosphorylation) were analyzed.
Main Results:
- MED1101 induced P2×7 receptor internalization in U937 cells within 30 minutes, lasting up to 12 hours.
- MED1101 inhibited monocyte migration and transmigration.
- The compound blocked Ca2+ influx and MAPK phosphorylation, indicating P2×7R antagonism.
Conclusions:
- MED1101 functions as a P2×7 receptor antagonist in U937 monocytes.
- MED1101's mechanism involves receptor internalization and inhibition of downstream signaling.
- MED1101 shows potential as a therapeutic agent for inflammatory conditions.
